Frontiers in Cell and Developmental Biology, Год журнала: 2024, Номер 12
Опубликована: Сен. 27, 2024
Язык: Английский
Immunologic Research, Год журнала: 2024, Номер 72(4), С. 592 - 604
Опубликована: Май 31, 2024
Abstract Cervical cancer affects thousands of women globally with recurring high-risk HPV infections being at the centre cervical pathology. Oncological treatment strategies are continually challenged by both chemoresistance and metastasis within patients. Although work hand-in-hand, targeting their individual mechanisms could prove highly beneficial for outcomes. Such targets include metastatic-promoting stem cell marker, CD44, which is abundant in cells common to metastatic mechanisms. Seeing that many existing advanced-stage regimes, such as platinum-based chemotherapy regimens, remain limited rarely curative, alternative options field immunology considered. The use immune checkpoint inhibition therapy, checkpoints, CTLA-4 PD-1/PD-L1, has shown promise an alternate standard care patients suffering from cancer. Therefore, this review aims assess whether can mitigate pathological effects CD44-induced EMT, metastasis,
Язык: Английский
Процитировано
6
Frontiers in Cell and Developmental Biology, Год журнала: 2024, Номер 12
Опубликована: Авг. 8, 2024
As a key factor in tumorigenesis, progression, recurrence and metastasis, the biological properties, metabolic adaptations immune escape mechanisms of CSCs are focus current oncological research. possess self-renewal, multidirectional differentiation tumorigenicity, their action can be elucidated by clonal evolution, hierarchical model dynamic model, which is widely recognized due to its better explanation function origin CSCs. The hypothesis involves cell-cell fusion, horizontal gene transfer, genomic instability microenvironmental regulation, together shape diversity In terms classification, include primary (pri-CSCs), precancerous stem cells (pre-CSCs), migratory (mig-CSCs), chemo-radiotherapy-resistant (cr-CSCs rr-CSCs), with each type playing specific role tumor progression. Surface markers CSCs, such as CD24, CD34, CD44, CD90, CD133, CD166, EpCAM, LGR5, offer possibility identifying, isolating, targeting but heterogeneity expression increase difficulty treatment. have adapted survival needs through reprogramming, showing ability flexibly switch between glycolysis oxidative phosphorylation (OXPHOS), well adjustments amino acid lipid metabolism. Warburg effect typifies profiles, altered glutamine fatty metabolism further contributes rapid proliferation able maintain stemness regulating networks characteristics, enhance antioxidant defences, adapt therapeutic stress. Immune another strategy for survival, effectively evade surveillance up-regulating PD-L1 promoting formation an immunosuppressive microenvironment. Together, these properties reveal multidimensional complexity underscoring importance deeper understanding biology development more effective strategies. future, therapies will on precise identification surface markers, intervention pathways, overcoming escape, aim improving relevance efficacy cancer treatments, ultimately patient prognosis.
Язык: Английский
Процитировано
5
Advances in biochemistry in health and disease, Год журнала: 2024, Номер unknown, С. 51 - 93
Опубликована: Янв. 1, 2024
Язык: Английский
Процитировано
3
Biomedicines, Год журнала: 2025, Номер 13(1), С. 225 - 225
Опубликована: Янв. 17, 2025
Malignant melanoma (MM) is a malignant tumor, resulting from mutations in melanocytes of the skin and mucous membranes. Its mortality rate accounts for 90% all dermatologic tumor mortality. Traditional treatments such as surgery, chemotherapy, radiotherapy are unable to achieve expected results due MM's low sensitivity, high drug resistance, toxic side effects. As treatment advances, immunotherapy targeted therapy have made significant breakthroughs MM demonstrated promising application prospects. However, heterogeneity immune response causes more than half patients not benefit clinical therapy, which delays patient's condition them suffer adverse events' The combination can help improve therapeutic effects, delay mitigate This review provides comprehensive overview current development status research progress checkpoints, genes, their inhibitors, with view providing reference MM.
Язык: Английский
Процитировано
0
Cancers, Год журнала: 2025, Номер 17(8), С. 1260 - 1260
Опубликована: Апрель 8, 2025
Human papillomavirus (HPV)-related lower genital cancers, including cervical cancer, anal squamous cell carcinoma (SCC), vaginal vulvar and penile pose a significant health burden, with approximately 45,000 new cases diagnosed annually. Current effective treatment modalities include chemoradiotherapy, systemic chemotherapy, immune checkpoint inhibitors (ICIs). The tumor microenvironment in HPV-related cancers is characterized by evasion mechanisms, the modulation of checkpoints such as PD-L1/PD-1. HPV oncoproteins E5, E6, E7 play crucial roles this process, altering expression inhibitory molecules recruitment cells. ICIs, programmed death protein 1 (PD-1) inhibitors, have shown efficacy enhancing response against HPV-associated tumors blocking proteins that allow cancer cells to evade surveillance. Recent studies demonstrated HPV-positive exhibit more favorable ICI-based therapies compared HPV-negative tumors. integration ICIs into regimens for has been supported several clinical trials. inclusion approach presents promising opportunity improving patient outcomes. Ongoing research trials are advancing our understanding therapeutic potential immunotherapy these cancers.
Язык: Английский
Процитировано
0
npj Vaccines, Год журнала: 2025, Номер 10(1)
Опубликована: Апрель 21, 2025
The clinical response to immune checkpoint blockade (ICB) is limited in the majority of patients with colorectal cancer. These proteins may not only inhibit T-cell-mediated antitumor immunity but also attenuate antigen presentation, including mutation-associated neoantigens. Here, we found that tumor B7-H3 levels limit therapeutic chemoradiotherapy locally-advanced rectal Knockdown significantly increased presentation increase T cell infiltration and killing ability, neoantigen-specific T-cell response. Blockade augmented cells remarkably enhanced efficacy neoantigen-based cancer vaccines combined radiotherapy, decreasing risk distant tumors vivo. Taken together, these results demonstrated targeting neoantigen as well radiotherapy by increasing extent cells, even for PD-1/PD-L1 blockade-resistant cancers.
Язык: Английский
Процитировано
0
International Journal of Molecular Sciences, Год журнала: 2024, Номер 25(9), С. 5045 - 5045
Опубликована: Май 6, 2024
V-set domain-containing T-cell activation inhibitor 1 (aliases VTCN1, B7H4) participates in tumour immune escape by delivering inhibitory signals to T cells. The purpose of this article was assess the B7H4 prognostic value solid cancers. Three databases were searched for relevant articles. main endpoints overall survival (OS), disease-specific (DSS), progression-free (PFS), recurrence-free (RFS), and disease-free (DFS). Appropriate hazard ratios (HRs) pooled. R studio software (version 4.0.3) used data analysis. Thirty-one studies met inclusion criteria. High expression associated with worse OS (HR = 1.52, 95% CI: 1.37–1.68) but not DSS 1.14, 0.49–2.63), RFS 1.77, 0.75–4.18), DFS 1.29, 0.8–2.09), or PFS 1.71, 0.91–3.2) patients is a poorer prognosis promising biomarker immunotherapeutic target various cancers because its activity cancer immunity tumourigenesis.
Язык: Английский
Процитировано
2
Experimental & Molecular Medicine, Год журнала: 2024, Номер 56(11), С. 2365 - 2381
Опубликована: Ноя. 11, 2024
Immune checkpoint proteins (ICPs) serve as critical regulators of the immune system, ensuring protection against damage due to overly activated responses. However, within tumor environment, excessive ICP activation weakens antitumor immunity. Despite development numerous blockade (ICB) drugs in recent years, their broad application has been inhibited by uncertainties about clinical efficacy. A thorough understanding regulation microenvironment is essential for advancing more effective and safer ICB therapies. Extracellular vesicles (EVs), which are pivotal mediators cell-cell communication, have extensively studied found play key roles functionality ICPs. Nonetheless, a comprehensive review summarizing current knowledge crosstalk between EVs ICPs environment lacking. In this review, we summarize interactions several widely well potential implications, providing theoretical basis further investigation EV-related therapeutic approaches.
Язык: Английский
Процитировано
2
International Journal of Drug Discovery and Pharmacology, Год журнала: 2024, Номер unknown, С. 100022 - 100022
Опубликована: Ноя. 26, 2024
Although previous reviews explored the roles of selected immune checkpoints (ICPs) in cardiovascular diseases (CVD) and cerebrovascular from various perspectives, many related aspects have yet to be thoroughly reviewed analyzed. Our comprehensive review addresses this gap by discussing cellular functions ICPs, focusing on tissue-specific microenvironment-localized transcriptomic posttranslational regulation ICP expressions, as well their functional interactions with metabolic reprogramming. We also analyze how 14 pairs including CTLA-4/CD86-CD80, PD1-PDL-1, TIGIT-CD155, regulate CVD pathogenesis. Additionally, covers ICPs modulating CD4+Foxp3+ regulatory T cells (Tregs), cells, innate CVDs diseases. Furthermore, we outline seven immunological principles guide development new ICP-based therapies for CVDs. This timely thorough analysis recent advancements challenges provide insights into role CVDs, Tregs, will support novel therapeutics strategies these
Язык: Английский
Процитировано
2
Life Sciences, Год журнала: 2024, Номер 353, С. 122919 - 122919
Опубликована: Июль 20, 2024
Язык: Английский
Процитировано
0